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were found to succumb to autoimmune disease and
lyn/ B cells were found to be hyperresponsive to B
cell receptor (BCR) ligation that the role of Lyn as a
negative regulator of signal transduction was revealed.
These seminal findings inB cells led to an understanding
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of the function of Lyn in multiple cell types and path-Australia
ways. Indeed, the diversity of Lyn’s targets has made it2The Ludwig Institute for Cancer Research
difficult to determine the key changes associated withMelbourne 3050
the pathology in knockout mice. Stimulatory roles forAustralia
Lyn in B cells have also been defined and although few
appear to be unique, dysregulation can also result in
disease. It is possible that through an assessment ofSummary
Lyn-dependent biochemical and cellular processes in
B cell development, pathways that contribute to immuneLyn, one of several Src-family tyrosine kinases in im-
dysregulation and disease susceptibility will be iden-mune cells, is noted for its ability to negatively regulate
tified.signaling pathways through phosphorylation of inhibi-
A Brief History of Lyn in B Cellstory receptors, enzymes, and adaptors. Somewhat
The Src family of nonreceptor protein tyrosine kinasesparadoxically, it is also a key mediator in several path-
comprises of Lyn, Src, Yes, Fgr, Fyn, Lck, Hck, Blk, andways of B cell activation, such as CD19 and CD180.
Yrk (Brown and Cooper, 1996). The lyn gene is localizedWhether Lyn functions to promote or inhibit immune
on human chromosome 8q13 (Yamanashi et al., 1987)cell activation depends on the stimulus and the devel-
and mouse chromosome 4qA1, although in mouse, aopmental state, meaning that the consequences of
pseudogene is present (Hibbs et al., 1995a). Lyn existsLyn activity are context dependent. The importance
in two isoforms, p53 and p56, arising from alternateof regulating Lyn activity is exemplified by the patho-
splicing of exon 2 (Stanley et al., 1991; Yi et al., 1991), butlogical conditions that develop in both lyn/ and lyn
no functional differencesbetween isoforms are currentlygain-of-function mice (lynup/up), including lethal anti-
known. lyn is expressed in all blood cells except T cells,body-mediated autoimmune diseases and myeloid
although lyn-expressing HTLV-transformed humanneoplasia. Here, we review the outcomes of altered
T cells have been reported (Yamanashi et al., 1989). SFKLyn activity within the framework of B cell develop-
structure and regulation have been reviewed recentlyment and differentiation and the circumstances that
(Lowell, 2004) and are summarized in Figure 1.appear to dictate the outcome.
Lyn is associatedwithBCRcomplexes containing IgM
or IgD (Yamanashi et al., 1991) as well as the B cell
costimulatory molecule CD19 (van Noesel et al., 1993).
Introduction
Lyn is rapidly phosphorylated and activated upon BCR
The challenge for molecular immunology is to determine crosslinking (Burkhardt et al., 1991), which correlates
how lymphocyte surface receptors that interact with with the tyrosine phosphorylation of Ig/ (Saouaf et
antigens transmit their signals into the nucleus to elicit al., 1994), suggesting a causative relationship. A lyn/
a stimulus that is appropriate to maintain the well being variant of the chicken B cell line DT40 exhibited delayed
of the host. Examination of normal and abnormal re- calcium influx after BCR ligation (Takata et al., 1994),
sponses has helped develop an understanding of the indicating a requirement for Lyn in promoting BCR-
molecular and cellular processes that govern the differ- induced calcium mobilization, although this data must
entiation of lymphocytes. The Src-family kinase (SFK) be viewed in the context of Lyn being the sole SFK in
Lyn has unique regulatory properties such that alter- these cells (Takata et al., 1994). Lynwas found to interact
ations in its activity or expression profoundly alter the with and phosphorylate tyrosine residues in Btk and
functioning of the immune system. Mice lacking Lyn or Syk kinases, HS1 protein, and the Cbl proto-oncogene
expressing a constitutively active form of Lyn transform product (reviewed in Gauld and Cambier [2004] and
the humoral immune system from being self-protective Lowell [2004]). After BCR engagement, Lyn and Fyn also
to self-destructive. Clearly, processes modulated by or associate with the p85 subunit of phosphoinositide-3
dependent on Lyn are critical to the immune system’s kinase (PI3K), an association that increasesPI3K activity
ability to appropriately discern self from nonself. (Pleiman et al., 1994). Lyn can also phosphorylate tyro-
Lyn is the predominant SFK in B cells, and based on sine(s) in the cytoplasmic domain of CD19 and in the
numerous biochemical tests, Lyn was initially assigned immunoreceptor tyrosine-based activation motifs (ITAMs)
a role in signal initiation. This was in keeping with both of the Ig/Ig subunits (Gauld and Cambier, 2004; Low-
the data and the general expectation of the function of ell, 2004). These data implied a prominent role for Lyn
SFK in signal transduction. It was not until lyn/ mice in the initiationof signals from theBCRand its costimula-
tors, making it quite surprising when lyn/ mice devel-
oped a lethal antibody-mediated glomerulonephritis*Correspondence: tarlinton@wehi.edu.au
(Hibbs et al., 1995b;Nishizumi et al., 1995). This phenom-3Present address: Peter MacCallumCancer Research Institute, Mel-
bourne, Australia. enon remained to a large extent inexplicable until lyn/
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Figure 1. Lyn Structure and Mode of Regu-
lation
Lyn is both myristylated and palmitylated lo-
calizing it to lipid rafts within the plasma
membrane (indicated by the lighter shading
of the plasma membrane). All SFKs are held
in an inactive state through phosphorylation
of a tyrosine residue in their C-terminal regu-
latory (R) domain by Csk family enyzmes. Csk
is itself regulated by membrane localization
through interaction with PAG/Cbp. Phos-
phorylation of the C-terminal tyrosine in SFKs
holds the enzymes in a closed conformation
through SH2 domain interactions. Lyn can be
activated by dephosphorylation of the C-ter-
minal regulatory tyrosine by CD45. CD45 is
shown within the lipid raft and acting to de-
phosphorylate Y508 for graphic purposes. Its
location varies over time and it is also able to
dephosphorylate Y397, inhibiting SFK activity
(Ashwell and D’Oro, 1999).
B cells were found to be both hyperresponsive to BCR active Lyn, pro-B cells are both normal in phenotype
and frequency when measured as a proportion of totalligation and resistant to the inhibitory consequences of
coligating FcRIIb1 or CD22 with the BCR (Chan et al., bonemarrow (BM) (Chan et al., 1997; Hibbs et al., 1995b,
2002; Nishizumi et al., 1995), suggesting that Lyn does1997, 1998a; Cornall et al., 1998; Nishizumi et al., 1998;
Smith et al., 1998). Thus, Lyn was revealed as a critical not control the proliferation or survival of pro-B cells. A
clear role for Lyn in the pre-B stage is only apparent innegative regulator of B cell activation.
B Cell Development combination with Fyn and Blk deficiency; progression
of B lineage cells lacking these three SFK is greatlyGiven the clear role for Lyn in signal transduction from
the BCR of mature B cells, it is reasonable to ask what diminished beyond the pre-B stage (Saijo et al., 2003).
This block is independent of Syk and not related torole it plays in the early stages of B cell development
and how such roles may differ from those in mature B phosphorylation of pre-BCR proximal signaling mole-
cules such as phospholipase C-2 (PLC-2) and Vavcells (Figure 2). It is somewhat surprising to find that
Lyn appears to play only a minor, or at least redundant, (Saijo et al., 2003). The current explanation is that signal-
ing through the pre-BCR in the absence of the threerole in pro- and pre-B cells. Although the absence of Lyn
alters the cycling status of multipotent hematopoietic SFKs fails to activate the atypical PKC and hence IKK,
IKK, and ultimately NF-B (Saijo et al., 2003); however,precursors (Harder et al., 2004), there is no indication
that this persists into the early stages of the B cell lin- NF-B-deficient mice do not show a similar phenotype
(Scott et al., 1993). Indeed, the normal pre-BCRproximaleage. In the absence of Lyn or presence of constitutively
Figure 2. Scheme of BCell Development and
the Importance of Lyn and Lyn-Regulated
Proteins in this Process
Conventional B cells arise from fetal liver and
adult BM, whereas B1a B cells originate in
fetal omentum and are thought to play an
important role in innate immunity, secreting
large amounts of low-affinity IgM antibody.
CD45 and CD19 are required for B1 B cell
development, and constitutively active Lyn
expands this compartment. SFK are critical
for conventional B cell development beyond
the pro-B cell stage as lyn/fyn/blk/
mice are blocked at this point. Lyn and Lyn
targets have important and unique roles be-
yond the immature B cell developmental stage,
arrows show where they enhance and bars where they inhibit a developmental step. Lyn is also critical for tempering plasma cell differentiation
as lyn/ mice show increased frequency of plasma cells. Marginal zone (MZ) B cell generation is blocked in both lyn/ and lynup/up mice.
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signal transduction in the absence of these SFKs sug- of enhanced deletion of self-reactive B cells, or that
the substrates targeted by Lyn vary with the degree orgests the defect may be in cell survival. Irrespective
of the molecular basis of the developmental arrest, it nature of BCR stimulation.
There is agreement that lyn/mice suffer from a defi-remains that Lyn contributes a positive role early in B
cell development. cit of mature B cells in the periphery and this is apparent
in the marginal zone (MZ) and follicular compartmentsCompletion of IgH gene rearrangement coincideswith
the first manifestation of Lyn as a negative regulator of of spleen and in recirculating B cells in lymph nodes
and BM (Chan et al., 1997; Hibbs et al., 1995b; NishizumiB cell activity. Although the developmentally earliest of
these examples is relatively indirect, it serves to resolve et al., 1995). Alteration of the number of MZ B cells is
considered to reflect changed BCR signaling thresh-the role of Lyn from that of other SFKs. More frequent
Ig gene rearrangement has been observed in the ab- olds, a phenomenon also seen in CD19/ and Aiolos/
mice (Engel et al., 1995; Rickert et al., 1995; Wang etsence of Lyn and presence of an Ig transgene (Meade
et al., 2002), suggesting that Lynmay contribute to allelic al., 1998). The loss of mature lyn/ B cells has been
attributed to enhanced apoptosis and to the rapid differ-exclusion at the IgL loci. Although this has not been
noted in other Ig transgenic systems (Cornall et al., 1998; entiation of mature B cells into antibody-secreting cells
(ASC) (Chan et al., 1997). Although a bcl-2 transgeneSeo et al., 2001), Lyn may well have a role in mediating
allelic exclusion as other components of the BCR have increased the number of B cells in the periphery of lyn/
mice, it neither altered the maturation state nor raisedbeen reported to be involved (Meade et al., 2004;
Schweighoffer et al., 2003). the B cell number to that seen in control bcl-2 transgenic
mice (Meade et al., 2002; M. Janas, M.L.H., and D.M.T.,Although lyn/ mice contain essentially normal B lin-
eage compartments through to the transitional stage in unpublished data), indicating that impaired cell survival
is not the only defect.spleen (Chan et al., 1997; Hibbs et al., 1995b; Nishizumi
et al., 1995), introducing Ig transgenes and their neo- The B1 B cell compartment remains controversial.
Early reports indicated that the majority of cells in theself determinants onto the lyn/ background revealed
Lyn as a negative regulator of BCR signaling in immature enlarged spleens of lyn/ mice were Mac-1 cyto-
plasmic IgM (Chan et al., 1997; Nishizumi et al., 1995),B cells in the BM (Cornall et al., 1998). For example, hen
egg lysozyme (HEL)-reactive lyn/ B cells are deleted classifying these cells as belonging to the B1 lineage,
although splenic B1 cells typically do not expressMac-1at this stage in the BM in the presence of soluble HEL,
whereas control B cells survive and enter the periphery (Hardy and Hayakawa, 2001). Other studies, however,
have reported either unchanged or a modest diminutionas anergic (Cornall et al., 1998). Thus, as for B cells
lacking the phosphatase SHP-1 (Cyster and Goodnow, in B1a B cell numbers in lyn/ mice (Hasegawa et al.,
2001; Hibbs et al., 1995b; Satterthwaite et al., 1998;1995), Lyn deficiency increases sensitivity to tolerance
induction in the BM. Curiously, an independent trans- Whyburn et al., 2003). This analysis is complicated by
the dramatically increased numbers of erythroid andgenic self-reactive system specific for DNAdid not show
a similar effect in the BM (Seo et al., 2001), highlighting Mac-1 myelomonocytic cells and their progenitors in
lyn/ spleen (Harder et al., 2001, 2004; Satterthwaite etthe potential contribution of either the antigen, the ge-
netic background, or both. One may speculate from the al., 1998). Superficially, a linkage between enhanced B1
B cells and autoimmune disease in lyn/ mice wouldnumerically normal immature B cell compartment in the
BM of nontransgenic lyn/ mice (Allman et al., 2001; fit with increases in this subpopulation in autoimmune
prone strains such as NZB and motheaten. However,Chan et al., 1997; Hibbs et al., 1995b; Nishizumi et al.,
1995) that any hyperresponsiveness of the BCR is com- lyn/ BM efficiently transfers anti-nuclear antibody de-
velopment into irradiated recipients (K.W.H., D.M.T., andpensated by a shift in the repertoire.
Analysis of lyn/ B cell subsets in the periphery has M.L.H., unpublished data), indicating that B1a cells are
not the source of these antibodies as BM transfers theseidentified this as a critical point requiring normal Lyn
activity. Although the number of immature B cells in cells poorly (Hardy and Hayakawa, 2001).
The final developmental compartment to be consid-lyn/ BM is normal (Chan et al., 1997; Hibbs et al.,
1995b;Nishizumi et al., 1995), there is a significant deficit ered is that of ASC. Analysis of serum Ig titers in lyn/
mice revealed a 10-fold increase in IgM (Hibbs et al.,in transitional B cells in the spleen (Allman et al., 2001;
Meade et al., 2002). When that compartment is subdi- 1995b; Nishizumi et al., 1995), with an equivalent in-
crease in IgM ASC in all lymphoid tissues (Hibbs et al.,vided, thedefect appears tobe in entry into the T1, 2, and
3 stages (Allmanet al., 2001). However, this conclusion is 1995b), although in adult lyn/ mice, the frequency of
IgG ASC and IgG levels were normal (Hibbs et al., 1995b;not unanimousbecause a developmental block between
T1 and T2 that is surmountable by a bcl-2 transgene Janas et al., 1999; Nishizumi et al., 1995). Although there
is general agreement with these observations, there ishas been reported (Meade et al., 2002), suggesting that
Lyn transmits a positive or survival signal for B cell little understanding of the underlying cause. Initial re-
ports suggested that the expansion in ASC was due torecruitment into the periphery, similar to that of Syk
(Turner et al., 1997). Although this result is consistent an expandedB1 population (Chan et al., 1997; Nishizumi
et al., 1995), but this observation remains contentiouswith a requirement for phosphorylation of Ig—a known
target of Lyn—for B cell survival (Torres et al., 1996), it (see above). An alternative is that the intrinsic BCR hy-
perresponsiveness of lyn/ B cells predisposes themis difficult to reconcile with the negative role identified
for Lyn in immature BM B cells (Cornall et al., 1998). to differentiate (Chan et al., 1997). It could be argued
that the tonic signaling required to sustain mature BPossible explanations are that Lyn has diametrically op-
posite roles in successive stages of B cell development, cells (Lam et al., 1997) is amplified or misinterpreted by
lyn/ B cells such that they differentiate into ASC atthat these observations are actually bothmanifestations
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Figure 3. Schematic Representation of Sig-
nal TransductionPathwaysModulatedby Lyn
in B Cells
Lyn contributes to positive regulation of sig-
naling through tyrosine phosphorylation of
ITAMs in the Ig and Ig components of the
BCR and in CD19. This role can be assumed
by other SFKs such as Fyn and Blk, and pro-
motes B cell activation through the recruit-
ment of Syk and PI3K. Lyn plays an essential
role in negative regulation of signaling
through its unique ability to phosphorylate
ITIMs in inhibitory cell surface receptors such
as FcRIIb1, CD22, PIR-B, and CD5 and a
potential inhibitory site on Syk (see text).
Whether CD72, PAG, and PD-1 are Lyn tar-
gets in vivo has yet to be confirmed. Positive
phosphorylation of Syk is redundant with
other SFKs. ITIM phosphorylation induces
the recruitment of inhibitory phosphatases
such as SHP-1/2 and SHIP-1, which down
modulate signaling. Lyn is also suspected to
be critical for the phosphorylation of PAG/
Cpb in B cells, thereby enabling Csk recruit-
ment to the plasma membrane where it may modulate SFK activity. Squares, SH3 domains; circles, SH2 domains; and P, phospho tyrosines.
The single P on each inhibitory receptor is indicative and not a representation of the true target number.
a high frequency. The fact that restricting the B cell gesting they are in an unstable equilibrium, but why this
breaks down in favor of activation over inhibition is apopulation to a single specificity by transgenesis does
not normalize the rate of differentiation (Cornall et al., critical question. Curiously, mice expressing a similarly
mutated version of Blk, introduced as a B and T lineage1998; Meade et al., 2002) indicates that specificity alone
is not the key determinant. Significantly, the DNA-reac- restricted transgene, have no reported predisposition
to autoimmunity but rather develop B lymphoid tumorstive Ig transgenic lyn/ model showed greatly dimin-
ished ASC formation (Seo et al., 2001) as did lyn/mice (Malek et al., 1998): no B cell tumors have arisen in
lynup/up mice (K.W.H., D.M.T., and M.L.H., unpublishedcarrying a hypomorphic allele of Btk (Whyburn et al.,
2003), suggesting that over production ofASC is respon- data). The different outcomes for Lyn- and Blk-gain-
of-function mutations may reflect differences in level,sive to BCR signaling, possibly transmitted through Btk.
Amplification of BCR Signaling by Lyn onset, or tissue distribution or different roles for these
SFK in B cell signaling.Bcells from lyn/mice showed essentially normal initia-
tion of BCR signaling, albeit delayed (Chan et al., 1997), The CD19-Lyn Amplification Loop. A second positive
role reported for Lyn is through its interactionwith CD19,indicating no absolute requirement for Lyn in these pro-
cesses. The involvement of Lyn in BCR signal amplifica- which together with CD21, CD81, and Leu 13 forms a
coreceptor complex that reduces the threshold of BCRtion, however, is made clear from two studies, whereas
unique roles for Lyn in positive signaling have been activation by up to 104-fold (Fearon and Carroll, 2000).
Although CD19 is considered critical to B cell activationfound outside the strict confines of the BCR, all with
implications for autoimmunity (Figure 3). due to association with Vav and PI3K (Wang et al., 2002),
it also associates with Lyn (van Noesel et al., 1993) andlynup/up Mice. B cells from lynup/up mice, homozygous
for a targeted Y508F mutation that results in sustained Fyn (Chalupny et al., 1995). Recently, CD19andLynwere
reported to form a signal amplification loop in mouse Bactivation of the kinase, show constitutive tyrosine
phosphorylation of positive signaling molecules, includ- cells in a process implying interdependence of Lyn and
CD19 activity (Fujimoto et al., 2000). The phenotypes ofing Syk and PLC-2, and display a heightened calcium
flux after BCR stimulation (Hibbs et al., 2002). Possibly lyn/ and CD19/ primary B cells do, however, differ
in both B cell biology and biochemistry (Chan et al.,to compensate for elevated baseline signaling, lynup/up B
cells down regulate surface IgM, CD45R, and the com- 1997; Engel et al., 1995; Hibbs et al., 1995b; Nishizumi
et al., 1995; Rickert et al., 1995), and there is also bio-plement receptor CD21 (Hibbs et al., 2002). Although
conventional B cell numbers are reduced, B1 B cells are chemical evidence showing Lyn and CD19 to be inde-
pendent (Xu et al., 2002), leaving this issue unresolved.increased, perhaps best explained by excess positive,
rather than negative, signals. Furthermore lynup/up mice CD19 phosphorylation requires SFK activity but which
doesn’t seem to matter (Xu et al., 2002), and CD19 isdevelop circulating autoantibodies and a lethal autoim-
mune glomerulonephritis pathologically distinct from constitutively phosphorylated inB cells from lynup/upmice
(Hibbs et al., 2002), indicating that Lyn can phosphory-that of lyn/ mice (Hibbs et al., 2002), again consistent
with the net change in B cell signaling being toward late CD19. One must conclude that these differences in
the Lyn dependence of CD19 phosphorylation reflectactivation. The situation, however, is quite complex as
there is also constitutive activation of inhibitory path- the efficiency of activating the SFK remaining in lyn/
B cells by the stimulus in use. This in turn might reflectways in lynup/up B cells (Hibbs et al., 2002). lynup/up periph-
eral B cells fail to proliferate after BCR stimulation, sug- the stimulus itself or possibly the nature of the B cells,
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which may alter as lyn/ mice age (Nishizumi et al., 1996) and therefore presumably defective in lyn/ B
cells. Lyn is also required for SHIP-1 phosphorylation1998). It is interesting to speculate, however, that the
constitutive phosphorylation of CD19 in lynup/up B cells (Hibbs et al., 2002), an event required to recruit p62dok
and its associated RasGAP, which act to antagonize the(Xu et al., 2002) may contribute to the autoimmune dis-
ease that develops in these mice (Hibbs et al., 2002), Ras pathway (Tamir et al., 2000; Tridandapani et al.,
1998). The fact that many of the regulatory functions ofgiven the documented association between elevated
CD19 andautoimmunedisease (Sato et al., 2000; Tedder FcRIIb1 require Lyn activity makes this connection a
potentially strong predisposing factor to the develop-et al., 1997).
RP105 and CD38. Two further examples of positive ment of autoimmune disease.
CD22. CD22, a B cell-restricted member of the sialo-signaling by Lyn in B cells are in the response to ligation
of RP105 (CD180) and CD38 (Chan et al., 1998b; Yasue adhesin family of molecules, is rapidly phosphorylated
on tyrosine after BCR ligation, facilitating recruitmentet al., 1997). lyn/ B cells fail to proliferate after RP105
ligation, which is mitogenic for control B cells. RP105 of numerous intracellular signaling molecules including
SHP-1, Lyn, Syk, PI3K, and PLC- (reviewed in Tamiractivates Lyn, PKCbI/II, and MEK (Chan et al., 1998b)
and forms part of the LPS receptor on B cells, acting and Cambier [1998]). CD22 is primarily an inhibitory re-
ceptor, as B cells from CD22/ mice show enhancedwith TLR4 in a MyD88-independent manner (Ogata et
al., 2000; Yazawa et al., 2003). This complex is reported BCR-induced Ca2 flux (O’Keefe et al., 1996; Otipoby et
al., 1996), whereas the activation of MAPK pathways isto recruit CD19, which is associated with Lyn and Vav
(Yazawa et al., 2003). Although RP105’s dependence suppressed when CD22 is coligated with the BCR but
enhanced when CD22 is separately ligated before BCRon Lyn could be via CD19, this is unlikely as RP105
stimulation induces no proliferation of lyn/ B cells engagement (Tooze et al., 1997). On the appropriate
genetic background and with age, CD22/ mice de-(Chan et al., 1998b), whereas CD19/ cells proliferate
at 30%of control levels (Yazawa et al., 2003), suggesting velop high titers of IgG anti-DNA antibodies but without
any apparent pathology (O’Keefe et al., 1999). Four stud-a direct relationship between Lyn and RP105. Coligation
of CD38 in the presence of IL5, although long recognized ies showed that CD22, Lyn, and SHP-1 form a regulatory
loop in B cells where, after BCR ligation, Lyn phosphory-as being mitogenic, is of uncertain physiological rele-
vance (Cockayne et al., 1998). It is, however, a Lyn- lates tyrosines in immunoreceptor tyrosine-based inhi-
bition motifs (ITIMs) of CD22, permitting the recruitmentdependent process with proliferation of B cells lacking
Lyn, Fyn, or both being greatly reduced. Lyn’s unique of SHP-1, which mediates the suppressive effects of
CD22 on Ca2 flux and MAPK activation (Chan et al.,role is the activation of Btk, whereas Lyn and Fyn coop-
erate in inducing optimal expression of the IL5R chain 1998a; Cornall et al., 1998; Nishizumi et al., 1998; Smith
et al., 1998). Cornall et al. (1998) manipulated gene dos-(Yasue et al., 1997).
Negative Regulation of BCR Signaling By Lyn age to simultaneously halve the availability of all three
components and showed this was sufficient for theGeneration of lyn/ mice, and the discovery of their
inherent predisposition to autoimmune disease and B development of BCR hyperresponsiveness in lyn/
CD22/SHP-1/ mice. Comparison of B cell develop-cell hyperresponsiveness revealed a role for Lyn in the
negative regulation of BCR signaling. Experiments ment in Lyn- and CD22-deficient mice, however, indi-
cates that only a subset of Lyn’s functions are mediatedin vitro showed that besides hyperproliferation in re-
sponse to BCR crosslinking, lyn/ primary B cells also through CD22. For example, both lyn/ and CD22/
mice share loss of MZB cells (Figure 2) and recirculatingshowed elevated MAPK activation, enhanced calcium
flux, and hyperactivation of Akt. These results define B cells in BM but are distinct in peripheral B cell popula-
tion size (Figure 2). The increase in serum IgM inCD22/multiple mechanisms for Lyn in establishing negative
feedback control of BCR signaling (Figure 3). As the mice is much less than in lyn/mice. The recent finding
that lynup/up primary B cells have constitutive phosphory-biochemistry of the predominant inhibitory activities of
Lyn in B cells has been recently reviewed (Gauld and lationofCD22andSHP-1 (Hibbs et al., 2002) strengthens
the interrelationship between Lyn, CD22, and SHP-1 butCambier, 2004; Lowell, 2004), this review focuses more
on the cell biology and the contribution these pathways suggests constitutive activation of this negative regula-
tory loop is insufficient to prevent autoimmunity.may make to the lyn/ phenotype.
Phosphorylating Inhibitory Receptors CD5. Expression of CD5 defines the B1a subset of B1
cells (Hardy and Hayakawa, 2001). BCR ligation on B1aFcRIIb1. Coligation of the BCR with the receptor for
the Fc portion of immunoglobulin, FcRIIb1, has long cells typically induces apoptosis rather than prolifera-
tion asoccurs in conventional Bcells, a responsedepen-been known to inhibit B cell activation (Phillips and Par-
ker, 1984). Indeed, FcRIIb1-deficient mice exhibit ele- dent on the presence of CD5 (Bikah et al., 1996). CD5
negatively regulates BCR stimulation via its constitutivevated antibody responses (Takai et al., 1996) and de-
velop rheumatoid arthritis and fatal glomerulonephritis association with SHP-1, an association that is Lyn de-
pendent (Ochi and Watanabe, 2000; Sen et al., 1999)on the C57BL/6 background (Bolland and Ravetch,
2000; Yuasa et al., 1999), just as many autoimmune- and consistent with lyn/ B1a cells proliferating in re-
sponse to BCR ligation (Ochi and Watanabe, 2000).prone strains are genetically unable to upregulate
FcRIIb1 expression after stimulation (Pritchard et al., Paired Immunoglobulin-like Receptor-B. Expression
of paired immunoglobulin-like receptor-B (PIR-B) is re-2000). Lyn is required for tyrosine phosphorylation of
FcRIIb1 and lyn/ B cells are resistant to the inhibitory stricted to B cells, myeloid cells, and dendritic cells
(DCs) (Hayami et al., 1997; Kubagawa et al., 1997). Aeffects of crosslinking FcRIIb1 with the BCR (Chan et
al., 1998a; Nishizumi et al., 1998). SHIP-1 recruitment to feature of the structure of PIR-B is the presence of four
ITIM-like sequences in the cytoplasmic tail (Maeda etFcRIIb1 is phosphorylation dependent (Ono et al.,
Immunity
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al., 1998), which appear to mediate the inhibitory activi- Lyn is the predominant B cell SFK, Lyn may well phos-
phorylate PAG in B cells. Consistent with this, we findties of PIR-B, including the inhibition of phosphorylation
of Syk, Btk, and PLC-2 (Maeda et al., 1999), by recruit- that Lyn coimmunoprecipitates with PAG, and phos-
phorylation of PAG in lyn/ primary B cells is compro-ing SHP-1 and/or SHP-2 (Blery et al., 1998; Yamashita
et al., 1998). InmousemacrophagesandBcells, tyrosine mised (our unpublished data). Activation of Lyn after
BCR ligation could therefore inhibit the activity of allphosphorylation of PIR-B with the subsequent binding
of SHP-1 is constitutive and Lyn dependent (Harder et SFK, including Lyn itself, by recruiting Csk to the rafts.
A similar scheme operates in mast cells where Lyn defi-al., 2001; Ho et al., 1999). B cells from PIR-B/ mice
hyperproliferate mildly in response to BCR ligation and ciency impairs PAG phosphorylation and Csk recruit-
ment (Odom et al., 2004). It will be of great interest toshow elevated levels of tyrosine phosphorylation even
at rest (Ujike et al., 2002). Surprisingly, conventional B determine the status of the remaining SFK in lyn/ B
cells to ascertain if Lyn deficiency promotes their activa-cell development is normal, as are resting serum Ig titers
(Ujike et al., 2002). The only B cell developmental abnor- tion due to defective regulation by PAG and Csk.
Phosphorylating a Negative Regulatory Site on Sykmality in PIR-B/mice is a 2-fold increase in the number
of peritoneal B1 cells (Ujike et al., 2002). After immuniza- Syk is an essential positive effector of BCR-stimulated
responses (Gauld and Cambier, 2004). After recruitmenttion with a T cell-dependent antigen, PIR-B/ mice
show an enhanced IgG1 and IgE response (Ujike et al., of Syk to the BCR, it becomes phosphorylated on multi-
ple tyrosines including three (Y-317, -342, and -346) in2002), although it is not clear if this is B cell intrinsic or
requires PIR-B/ DCs. Interestingly, lyn/ B cells are the linker region separating the tandem SH2 domains
from the C-terminal catalytic domain (Keshvara et al.,hyperresponsive to IL4, switching to IgG1 and IgE at
10-fold lower concentrations of IL4 than those required 1998). The phosphorylation of Y-317 creates a binding
site for c-Cbl (Yankee et al., 1999), which can servefor control B cells (Janas et al., 1999), suggesting possi-
ble cooperation between Lyn and PIR-B. as a negative regulator of BCR signaling. DT40 B cells
lacking Lyn hypophosphorylate Syk Y-317, leading toPhosphorylating Adaptor Molecules
Downstream of Tyrosine Kinase. Lyn is required for elevated production of IP3 and an amplified calcium
signal (Hong et al., 2002). Although this result needs tophosphorylation of p62dok (Dok-1) in Bcells (Yamanashi
et al., 2000). The downstream of tyrosine kinase (Dok) be confirmed in other cell systems in which Lyn is not
the sole SFK, it broadens our view of how Lyn mayfamily of adaptor molecules modulates immunorecep-
tor, cytokine, and growth factor signaling in a variety negatively regulate BCR signaling to includemodulating
the turnover of positive signalosomes.of hematopoietic lineages (Lowell, 2004). Inhibition by
p62dok is mediated by its phosphorylation-dependent Complementation and Synergy
There have been a limited number of reports of therecruitment ofRasGAP (Yamanashi andBaltimore, 1997)
andCsk (Neet andHunter, 1995). It is not clear, however, phenotype of lyn/ mice being modified by genetic
crosses and these are summarized below.whether the failure to observe phospho-p62dok in lyn/
B cells is due to the direct action of Lyn on p62dok, the lyn x Btk. Given the profound block in B cell activation
apparent in B cells lacking Btk, it is not surprising thatfailure to phosphorylate either FcRIIb1 or SHIP-1, or
both (see above). MAPK phosphorylation and B cell pro- loss of this kinase dominates the B cell phenotype of
lyn/Btk/ mice (Satterthwaite et al., 1998; Takeshitaliferation are not inhibited in p62dok/ B cells by coen-
gagement of the BCR and FcRIIb1 as they are in con- et al., 1998). lyn/Btk/ B cells behave like Btk/ B
cells, with low titers of serum IgM and IgG, no prolifera-trols but calcium release is (Yamanashi et al., 2000).
Little has been reported on the biology of p62dok/ tion in response to BCR ligation, and loss of B1 cells.
Surprisingly, the number of B cells in the spleens ofB cells, but serum IgM titers are lower than controls
(Yamanashi et al., 2000), suggesting this is Lyn indepen- lyn/Btk/ mice is significantly reduced compared to
either parent (Satterthwaite et al., 1998; Takeshita etdent. Lyn may also be involved in the activation of Dok-3,
which is expressed in B cells and macrophages, phos- al., 1998), indicating a degree of independence in the
signaling pathways controlled by these kinases. Need-phorylated by SFK after BCR ligation, and functions
to diminish JNK activity through recruitment of SHIP-1 less to say, lyn/Btk/mice do not develop autoimmu-
nity, nor do they have the splenomegaly or expanded(Lemay et al., 2000; Robson et al., 2004).
Phosphoprotein Associated with Glycosphingolipid- myeloid population characteristic of Lyn deficiency (Sat-
terthwaite et al., 1998; Takeshita et al., 1998). AnotherEnriched Microdomains. Phosphoprotein associated
with glycosphingolipid-enrichedmicrodomains (PAG) or revealing cross introduced a hypomorphic allele of btk
onto the lyn/Btk/ background (Whyburn et al., 2003).Csk binding protein (Cbp) has emerged as a potentially
critical regulator of SFK activity through its association B cells from these mice retained aspects of lyn/ BCR
hyperresponsiveness but lost the splenomegaly and ex-with Csk (Brdicka et al., 2000; Kawabuchi et al., 2000).
Like Dok, PAG contains several tyrosines that may be panded myeloid compartment characteristic of lyn/
mice, did not develop significant anti-DNA antibody ti-phosphorylated and thus serve as potential protein
binding sites (Brdicka et al., 2000). Based on analysis ters, and had very little serum IgM (Whyburn et al., 2003).
This last point suggests that the high frequency of IgMof T cells where PAG has been well studied (Brdicka et
al., 2000; Torgersen et al., 2001), it is suggested that ASC in lyn/ mice is dependent on a process that re-
quires full Btk activity; however, it is unclear what thatin the resting state, lipid raft-associated and tyrosine-
phosphorylated PAG recruits Csk to the plasma mem- is and whether it is B cell intrinsic.
lyn x CD19. This cross also prevented the develop-brane where it phosphorylates the C-terminal tyrosine
of SFKs, promoting their inactivation (Hata et al., 1994). ment of the autoimmune disease that afflicts the lyn/
parent (Hasegawa et al., 2001). From the perspective ofBecause PAG resides exclusively in lipid rafts where
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B cell biology, the CD19 phenotype was dominant; the Concluding Remarks
lyn/CD19/ mice had increases in IgM levels on pe- Lyn is the predominantly expressed SFK in B cells and
ripheral B cells, an absence of peritoneal B1 cells, and has both positive and negative regulatory roles in BCR-
T-dependent responses similar to theirCD19/ parents induced signal transduction. Accumulating evidence in-
(Hasegawa et al., 2001). Lyn deficiency was, however, dicates that the positive functions of Lyn after BCR liga-
apparent in the reduced B cell numbers in the periphery, tion are probably context dependent, such that Lyn can
the persistence of splenomegaly, and the expanded be substituted by other SFK depending on the nature
splenic myeloid population (Hasegawa et al., 2001). For of the stimulation. The irreplaceable function of Lyn in
all intents and purposes, the loss of negative regulation B cells is to set the threshold of negative feedback
apparent in lyn/ B cells is rendered moot by the loss control of signaling after BCR ligation and this is
of signaling due to CD19 deletion. achieved by multiple mechanisms that may work syner-
lyn x fyn. Two groups have made lyn/fyn/ mice. gistically and independently. Important future chal-
One noted significantly increasedmortality due to inheri- lenges are to verify in vitro findings with in vivo models
tance of altered kidney physiology from the fyn/parent in order to explain how loss of Lyn leads to the produc-
combining with autoantibodies from the lyn/ parent tion of high titer autoantibodies when transgenic model
to produce a more lethal combination (Yu et al., 2001). systems suggest that Lyn deficiency enhances the in-
Interestingly, this study noted a 10-fold reduction in rela- duction ofB cell tolerance. The role of Lyn in establishing
tive anti-nuclear antibody (ANA) titers in lyn/fyn/ signaling thresholds in other lineages of hematopoietic
mice compared to the lyn/ parents, which could reflect cells and the role of these cells in the development of
either the loss of Fyn’s positive role in B cell differentia- autoimmune disease may provide valuable insights into
tion or an aspect of a Fyn-related T cell defect. The autoimmune disease etiology. These studies may well
second study found lyn/fyn/ B cells to behave and contribute not only to the knowledge of B cell biology
look like lyn/ B cells with some exceptions (Horikawa but also to the development of pharmaceutical reagents
et al., 1999). Loss of Fyn reduced lyn/ B cell hyperres- for better management of human diseases that may
ponsiveness to BCR ligation, although not to control havedysregulatedLyn-related pathways as contributing
levels but enough to suggest a positive role for Fyn in or causative factors.
BCR signaling in the absence of Lyn (Horikawa et al.,
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